Market Overview

The Assistance Fund Opens New Program for Individuals with Alpha-1 Antitrypsin Deficiency

Share:

Eligible patients can receive financial support for copayments,
health insurance premiums and incidental medical expenses

Today, The Assistance Fund, an independent charitable patient assistance
foundation that helps patients and families facing high medical
out-of-pocket costs, announced the launch of a new program for
individuals with Alpha-1 Antitrypsin Deficiency (Alpha-1). The program
helps provide eligible patients with the financial resources they need
to pay for out-of-pocket medical costs incurred as a result of their
condition.

Alpha-1 is a genetic disorder thought to be caused by a mutation in a
gene that tells the body to make a protein called Alpha-1 antitrypsin
protein or AAT. AAT is produced by the liver and helps protect the lungs
from inflammation.1 When AAT is functioning abnormally it
cannot be released from the liver to reach the lungs, which creates a
buildup. This can result in liver disease or lung disease, including
emphysema, severe scarring (cirrhosis of the liver) or even liver cancer.1,2

"The launch of the Alpha-1 Antitrypsin Deficiency Financial Assistance
Program is an important milestone for patients living with this
condition," said Mark P. McGreevy, President and CEO, The Assistance
Fund. "We are proud to be able to help alleviate some of the financial
burdens for these patients. Alpha-1 is a rare disease, but for those who
have it the impact on their lives financially, physically and mentally
can be significant."

Alpha-1 affects approximately 1 in 2,000 to 1 in 5,000 individuals but
it is often misdiagnosed or underdiagnosed because the initial symptoms
may mimic other conditions, such as asthma or chronic obstructive
pulmonary disease (COPD).1 There is no cure for Alpha-1, but
once officially diagnosed by a blood test, there are a number of
treatment courses patients can take.3

"The Alpha-1 Foundation applauds The Assistance Fund for opening their
Alpha-1 Antitrypsin Deficiency Financial Assistance Program," said Henry
Moehring, President and CEO of the Alpha-1 Foundation. "The financial
burden surrounding access to therapy and care in our community and in
the rare disorder community at large is a barrier we must all continue
to focus on. We look forward to the impact TAF's programs will have in
reducing that burden for Alpha-1 patients and their families."

To learn more or determine eligibility for financial support from The
Assistance Fund, individuals should visit tafcares.org or
call 855-275-9030 to speak with a patient advocate.

A list of all the programs available at The Assistance Fund can be found
on the website tafcares.org.

About The Assistance Fund

The Assistance Fund is an independent charitable patient assistance
foundation that helps patients and families facing high medical
out-of-pocket costs by providing financial assistance for their
copayments, coinsurance, deductibles and other health-related expenses.
The Assistance Fund currently manages more than 40 funds – each of which
covers the FDA-approved medications that treat a specific disease. Since
its founding in 2009, The Assistance Fund has helped more than 73,000
adults and children access the medicines they need to stay healthy or
manage a chronic condition. To learn more about The Assistance Fund, or
for information on how to donate, please visit tafcares.org.

References

1. "Review of α1-Antitrypsin Deficiency." American Journal of
Respiratory and Critical Care Medicine. 2011. Retrieved from https://www.atsjournals.org/doi/full/10.1164/rccm.201108-1428CI.

2. "Alpha-1 antitrypsin deficiency." Genetics Home Reference. 2018.
Retrieved from https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency.

3. "Alpha-1 Antitrypsin Deficiency." National Heart, Lung, and Blood
Institute. Retrieved from https://www.nhlbi.nih.gov/health-topics/alpha-1-antitrypsin-deficiency.

View Comments and Join the Discussion!